为什么在二次中风预防中不能忽视遗传学:亚洲的CYP2C19挑战
Anushika Raheja1, Deidre Anne De Silva1, Kaavya Narasimhalu1,2
1Department of Neurology, National Neuroscience Institute (Singapore General Hospital campus), Singapore (A.R., D.A.D.S., K.N.).
Stroke
|December 22, 2025
概括
基因型引导的抗血小板治疗显著降低了亚洲人具有CYP2C19功能丧失等位基因的复发性中风风险. 实施精准医学,包括药物基因组学,对于在亚洲有效预防中风至关重要.
科学领域:
- 心血管医学 心血管医学
- 遗传学 遗传学是一种遗传学.
- 公共卫生 公共卫生
背景情况:
- 脑卒中是全球主要的健康问题,特别是在亚洲.
- 在亚洲人中常见的CYP2C19功能丧失等位基因损害了克洛皮多格雷尔在预防中风方面的有效性.
- 这种遗传变异对二次中风预防构成重大障碍.
研究的目的:
- 评估基因型导向抗血小板治疗对亚洲人群中继性中风预防的疗效.
- 解决阻碍临床采用药物基因组指导性中风预防策略的挑战.
- 突出精准医学在减少中风复发和亚洲医疗负担方面的潜力.
主要方法:
- 对临床试验证据的审查,包括CHANCE-2试验.
- 分析CYP2C19基因型对抗血小板药物的疗效的影响.
- 基因型导向治疗的可行性和成本效益的评估.
主要成果:
- 基因型导向的替代品,如蒂卡格勒罗和西洛斯塔,显著降低了CYP2C19功能丧失载体中复发性中风风险.
- 尽管已证明有好处,但临床实施受到基础设施,成本和培训差距的限制.
- 基因型导向治疗被证明是可行的和具有成本效益的.
结论:
- 以药物基因组学为指导的精确抗血小板策略对于亚洲有效的二次中风预防至关重要.
- 需要紧急实施基因型导向疗法,更新指南和公平获取.
- 将药物基因组学纳入常规中风护理可以减少中风复发,残疾和医疗保健费用.
相关概念视频
Human Genetics
1.4K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
1.4K
Single Nucleotide Polymorphisms-SNPs
17.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.8K
Atherosclerosis III: Management
291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
178
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
178
Coronary Artery Disease IV: Preventive Measures
564
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
564
Coronary Artery Disease I: Introduction
846
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
846


